ОСОБЕННОСТИ ОБМЕНА ЛИПИДОВ ПРИ HCV-ИНФЕКЦИИ

Жизненный цикл вируса гепатита С (HCV) осуществляется при участии обмена липидов в клетках печени. Цель - провести обзор молекулярных механизмов липидного обмена в клетках печени при HCV-инфекции для определения их значения в формировании стеатоза печени. Результаты. Показано влияние HCV-инфекции на обмен липидов в гепатоцитах, взаимосвязь метаболитов холестерина и иммунного ответа на HCV-инфекцию, определены генетические аспекты липидного обмена при HCV-инфекции. Заключение. Внутрипеченочный жизненный цикл HCV существенно зависит от продукции холестерина и путей липогенеза. При инфицировании HCV активирует метаболизм липидов хозяина путем различных молекулярных механизмов, которые могут способствовать развитию стеатоза печени.

Popescu C.I., Riva L., Vlaicu O., Farhat R., Rouillé Y., Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) 2014; 3(4): 892-921. https://doi.org/10.3390/biology3040892

Modaresi Esfeh J., Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol. Rep. (Oxf.) 2016; 4(1): 24-9. https://doi.org/10.1093/gastro/gov040

Singaravelu R., O’Hara S., Jones D.M., Chen R., Taylor N.G., Srinivasan P., et al. MicroRNAs regulate the immunometabolic response to viral infection in the liver. Nat. Chem. Biol. 2015; 11(12): 988-93. https://doi.org/10.1038/nchembio.1940

Russell D.W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta. 2000; 1529(1-3): 126-35. https://doi.org/10.1016/s1388-1981(00)00142-6

Syed G.H., Khan M., Yang S., Siddiqui A. Hepatitis C Virus lipoviroparticles assemble in the Endoplasmic Reticulum (ER) and bud off from the ER to the Golgi compartment in COPII Vesicles. J. Virol. 2017; 91(15): e00499-17. https://doi.org/10.1128/JVI.00499-17

Grove J., Nielsen S., Zhong J., Bassendine M.F., Drummer H.E., Balfe P., et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 2008; 82(24): 12020-9. https://doi.org/10.1128/JVI.01569-08

Cheng J.J., Li J.R., Huang M.H., Ma L.L., Wu Z.Y., Jiang C.C., et al. CD36 is a co-receptor for hepatitis C virus E1 protein attachment. Sci. Rep. 2016; 6: 21808. https://doi.org/10.1038/srep21808

Flores R., Owens R.A., Taylor J. Pathogenesis by subviral agents: viroids and hepatitis delta virus. Curr. Opin. Virol 2016; 17: 87-94. https://doi.org/10.1016/j.coviro.2016.01.022

Feneant L., Levy S., Cocquerel L. CD81 and hepatitis C virus (HCV) infection. Viruses 2014; 6(2): 535-72. https://doi.org/10.3390/v6020535

Tong Y., Zhu Y., Xia X., Liu Y., Feng Y., Hua X., et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J. Virol. 2011; 85(6): 2793-802. https://doi.org/10.1128/JVI.01818-10

Howell K.W., Meng X., Fullerton D.A., Jin C., Reece T.B., Cleveland J.C. Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J. Surg. Res. 2011; 171(1): e27-31. https://doi.org/10.1016/j.jss.2011.06.033

Westhaus S., Bankwitz D., Ernst S., Rohrmann K., Wappler I., Agné C., et al. Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein. Hepatology. 2013; 57(5): 1716-24. https://doi.org/10.1002/hep.26190

Horner S.M. Activation and evasion of antiviral innate immunity by hepatitis C virus. J. Mol. Biol. 2014; 426(6): 1198-209. https://doi.org/10.1016/j.jmb.2013.10.032

Li K., Lemon S.M. Innate immune responses in hepatitis C virus infection. Semin. Immunopathol 2013; 35(1): 53-72. https://doi.org/10.1007/s00281-012-0332-x

Westbrook R.H., Dusheiko G. Natural history of hepatitis C. J. Hepatol. 2014; 61(1 Suppl.): S58-68. https://doi.org/10.1016/j.jhep.2014.07.012

Fierro N.A., Gonzalez-Aldaco K., Roman S., Panduro A. The immune system and viral hepatitis. In: Muriel P. Liver Pathophysiology: Therapies & Antioxidants. Waltham, MA: Elsevier; 2017: 129-39.

Fierro N.A., González-Aldaco K., Torres-Valadez R., Trujillo-Trujillo M.E., Roman S., Trujillo-Ochoa J.L., et al. Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients. Mem. Inst. Oswaldo Cruz. 2015; 110(2): 267-71. https://doi.org/10.1590/0074-02760140377

Lund E.G., Kerr T.A., Sakai J., Li W.P., Russell D.W. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J. Biol. Chem. 1998; 273(51): 34316-27. https://doi.org/10.1074/jbc.273.51.34316

Xiang Y., Tang J.J., Tao W., Cao X., Song B.L., Zhong J. Identification of Cholesterol 25-Hydroxylase as a novel host restriction factor and a part of the primary innate immune responses against Hepatitis C Virus Infection. J. Virol. 2015; 89(13): 6805-16. https://doi.org/10.1128/JVI.00587-15

Park K., Scott A.L. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J. Leukoc. Biol. 2010; 88(6): 1081-7. https://doi.org/10.1189/jlb.0610318

Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996; 383(6602): 728-31. https://doi.org/10.1038/383728a0

Radhakrishnan A., Ikeda Y., Kwon H.J., Brown M.S., Goldstein J.L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl. Acad. Sci. USA. 2007; 104(16): 6511-8. https://doi.org/10.1073/pnas.0700899104

Wahli W., Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 2012; 23(7): 351-63. https://doi.org/10.1016/j.tem.2012.05.001

Chen Y., Wang S., Yi Z., Tian H., Aliyari R., Li Y., et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci. Rep. 2014; 4: 7242. https://doi.org/10.1038/srep07242

Wu J.M., Skill N.J., Maluccio M.A. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford). 2010; 12(9): 625-36. https://doi.org/10.1111/j.1477-2574.2010.00207.x

Yano M., Ikeda M., Abe K., Dansako H., Ohkoshi S., Aoyagi Y., et al. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob. Agents Chemother. 2007; 51(6): 2016-27. https://doi.org/10.1128/AAC.01426-06

McRae S., Iqbal J., Sarkar-Dutta M., Lane S., Nagaraj A., Ali N., et al. The Hepatitis C virus-induced NLRP3 inflammasome activates the Sterol Regulatory Element-binding Protein (SREBP) and regulates lipid metabolism. J. Biol. Chem. 2016; 291(7): 3254-3267. https://doi.org/10.1074/jbc.M115.694059

Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS J. 2009; 276(3): 616-21. https://doi.org/10.1111/j.1742-4658.2008.06806.x

Chao T.C., Su W.C., Huang J.Y., Chen Y.C., Jeng K.S., Wang H.D., et al. Proline-serine-threonine phosphatase-interacting protein 2 (PSTPIP2), a host membrane-deforming protein, is critical for membranous web formation in hepatitis C virus replication. J. Virol. 2012; 86(3): 1739-49. https://doi.org/10.1128/JVI.06001-11

Romero-Brey I., Merz A., Chiramel A., Lee J.Y., Chlanda P., Haselman U., et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 2012; 8(12): e1003056. https://doi.org/10.1371/journal.ppat.1003056

Silbernagel G., Kovarova M., Cegan A., Machann J., Schick F., Lehmann R., et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J. Clin. Endocrinol. Metab. 2012; 97(12): E2288-92. https://doi.org/10.1210/jc.2012-2152

Lyn R.K., Singaravelu R., Kargman S., O’Hara S., Chan H., Oballa R., et al. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes. Sci. Rep. 2014; 4: 4549. https://doi.org/10.1038/srep04549

Huang H., Sun F., Owen D.M., Li W., Chen Y., Gale M., et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. USA. 2007; 104(14): 5848-53.

Simon A. Cholesterol metabolism and immunity. N. Engl. J. Med. 2014; 371(20): 1933-5. https://doi.org/10.1056/NEJMcibr1412016

Hotamisligil G.S. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017; 542(7640): 177-85. https://doi.org/10.1038/nature21363

Ogawa E., Furusyo N., Kajiwara E., Nomura H., Dohmen K., Takahashi K., et al. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Res. 2014; 104: 102-9. https://doi.org/10.1016/j.antiviral.2014.01.004

Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 2015; 15(2): 104-16. https://doi.org/10.1038/nri3793

Machida K., Cheng K.T., Sung V.M., Levine A.M., Foung S., Lai M.M. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J. Virol. 2006; 80(2): 866-74. https://doi.org/10.1128/JVI.80.2.866-874.2006

Huang M., Jiang J.D., Peng Z. Recent advances in the anti-HCV mechanisms of interferon. Acta Pharm. Sin. B. 2014; 4(4): 241-7. https://doi.org/10.1016/j.apsb.2014.06.010

Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014; 6(10): a016295. https://doi.org/10.1101/cshperspect.a016295

Mackenzie J.M., Khromykh A.A., Parton R.G. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe. 2007; 2(4): 229-39. https://doi.org/10.1016/j.chom.2007.09.003

Sheridan D.A., Bridge S.H., Felmlee D.J., Crossey M.M., Thomas H.C., Taylor-Robinson S.D., et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J. Hepatol. 2012; 57(1): 32-8. https://doi.org/10.1016/j.jhep.2012.02.017

Townsend K., Meissner E.G., Sidharthan S., Sampson M., Remaley A.T., Tang L., et al. Interferon-free treatment of hepatitis C virus in HIV/Hepatitis C virus-coinfected subjects results in increased serum low-density lipoprotein concentration. AIDS Res. Hum. Retroviruses. 2016; 32(5): 456-62. https://doi.org/10.1089/AID.2015.0170

Grebely J., Feld J.J., Applegate T., Matthews G.V., Hellard M., Sherker A., et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology. 2013; 57(6): 2124-34. https://doi.org/10.1002/hep.26263

Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003; 4(1): 69-77. https://doi.org/10.1038/ni875

O’Connor K.S., George J., Booth D., Ahlenstiel G. Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. World J. Gastroenterol. 2014; 20(47): 17830-8. https://doi.org/10.3748/wjg.v20.i47.17830

Donnelly R.P., Dickensheets H., O’Brien T.R. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011; 32(9): 443-50. https://doi.org/10.1016/j.it.2011.07.002

Cacoub P. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther. Adv. Infect. Dis. 2016; 3(1): 3-14. doi: 10.1177/2049936115585942

Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401. https://doi.org/10.1038/nature08309

Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41(10): 1105-9. https://doi.org/10.1038/ng.449

Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O’Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801. https://doi.org/10.1038/nature08463

Li J.H., Lao X.Q., Tillmann H.L., Rowell J., Patel K., Thompson A., et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010; 51(6): 1904-11. https://doi.org/10.1002/hep.23592

Phillips M.C. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014; 66(9): 616-23. https://doi.org/10.1002/iub.1314

Benga W.J., Krieger S.E., Dimitrova M., Zeisel M.B., Parnot M., Lupberger J., et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology. 2010; 51(1): 43-53. https://doi.org/10.1002/hep.23278

Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000; 1: 507-37. https://doi.org/10.1146/annurev.genom.1.1.507

Roman S., Ojeda-Granados C., Ramos-Lopez O., Panduro A. Genome-based nutrition: An intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis. World J. Gastroenterol. 2015; 21(12): 3449-61. https://doi.org/10.3748/wjg.v21.i12.3449

Price D.A., Bassendine M.F., Norris S.M., Golding C., Toms G.L., Schmid M.L., et al. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut. 2006; 55(5): 715-8. https://doi.org/10.1136/gut.2005.079905

Wozniak M.A., Itzhaki R.F., Faragher E.B., James M.W., Ryder S.D., Irving W.L. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology. 2002; 36(2): 456-63. https://doi.org/10.1053/jhep.2002.34745

Lye S.H., Chahil J.K., Bagali P., Alex L., Vadivelu J., Ahmad W.A., et al. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PLoS One. 2013; 8(4): e60729. https://doi.org/10.1371/journal.pone.0060729

Syed G.H., Tang H., Khan M., Hassanein T., Liu J., Siddiqui A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J. Virol. 2014; 88(5): 2519-29. https://doi.org/10.1128/JVI.02727-13

Caruz A., Neukam K., Rivero-Juárez A., Herrero R., Real L.M., Camacho A., et al. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. Genes Immun. 2014; 15(1): 16-24. https://doi.org/10.1038/gene.2013.56

Pineda J.A., Caruz A., Di Lello F.A., Camacho A., Mesa P., Neukam K., et al. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS. 2011; 25(11): 1415-20. https://doi.org/10.1097/QAD.0b013e328348a7ac

Albecka A., Belouzard S., Op de Beeck A., Descamps V., Goueslain L., Bertrand-Michel J., et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology. 2012; 55(4): 998-1007. https://doi.org/10.1002/hep.25501

Schertzer J.D., Steinberg G.R. Immunometabolism: the interface of immune and metabolic responses in disease. Immunol. Cell Biol. 2014; 92(4): 303. https://doi.org/10.1038/icb.2014.12

François-Souquière S., Makuwa M., Bisvigou U., Kazanji M. Epidemiological and molecular features of hepatitis B and hepatitis delta virus transmission in a remote rural community in central Africa. Infect. Genet. Evol. 2016; 39: 12-21. https://doi.org/10.1016/j.meegid.2015.12.021

Felmlee D.J., Hafirassou M.L., Lefevre M., Baumert T.F., Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013; 5(5): 1292-324. https://doi.org/10.3390/v5051292

Leu G.Z., Lin T.Y., Hsu J.T. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 2004; 318(1): 275-80. https://doi.org/10.1016/j.bbrc.2004.04.019

Poli G., Biasi F., Leonarduzzi G. Oxysterols in the pathogenesis of major chronic diseases. Redox Biol. 2013; 1(1): 125-30. https://doi.org/10.1016/j.redox.2012.12.001

Syed G.H., Amako Y., Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol. Metab. 2010; 21(1): 33-40. https://doi.org/10.1016/j.tem.2009.07.005

Schertzer J.D., Steinberg G.R. Immunometabolism: the interface of immune and metabolic responses in disease. Immunol. Cell Biol. 2014; 92(4): 303. https://doi.org/10.1038/icb.2014.12